Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Clopidogrel Taw Pharma (previously Clopidogrel Mylan)“
Suchtreffer
Begriffe & Kennungen
Clopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Other concomitant therapy:
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other co
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Proton Pump Inhibitors (PPI): Omeprazole 80 mg once daily administered either at the same time as clopidogrel
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Rifampicin strongly induces CYP2C19, resulting in both an increased level of clopidogrel active metabolite and
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Rosuvastatin: Clopidogrel has been shown to increase rosuvastatin exposure in patients by 2-fold (AUC) and 1.3
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · SSRIs: since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administratio
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel. Ant
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers or antacids in
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thro
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 Undesirable effects · 1
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · Adverse reactions that occurred either during clinical studies or that were spontaneously reported are present
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · Clopidogrel has been evaluated for safety in more than 44,000 patients, who have participated in clinical stud
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · In ACTIVE A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA g
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus A
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both gro
Eintrag öffnen